Boston Consulting Group (BCG) made an interesting article showing DeepTech VC funds have similar returns to traditional VC, despite the high complexity and cash needs of building hardware and biomolecules.
DrugDevelopment has no shortage of complexity or investment risk but the impact and social benefit are bar none. Great to see organizations diving into the numbers to prove biotech and other categories of deep tech maintain strong returns.
Read the full article from BCG here.
